KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Daily Values

Growth Metrics

Astrazeneca (AZN) Capital Leases (2018)

Astrazeneca has reported Capital Leases over the past 2 years, most recently at $361.0 for Q4 2018.

For Q4 2018, Capital Leases changed N/A year-over-year to $361.0; the TTM value through Dec 2018 reached $361.0, changed N/A, while the annual FY2018 figure was $361.0, N/A changed from the prior year.
Capital Leases for Q4 2018 was $361.0 at Astrazeneca, up from -$84.0 million in the prior quarter.
Over five years, Capital Leases peaked at $361.0 in Q4 2018 and troughed at $361.0 in Q4 2018.